Actively Recruiting
Advanced Translational Research on Childhood Leukemia
Led by Chinese University of Hong Kong · Updated on 2026-02-03
300
Participants Needed
1
Research Sites
413 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prognosis of children with leukemia, the most common pediatric cancer, has improved markedly. Yet, relapse still occurs in 15-40% of patients with a probability of survival of \<50%, which is unlikely to be boosted by intensification of standard chemotherapy due to overwhelming toxicity. The advent of effective and safe targeted therapies for high-risk cases is therefore imperative. This study constitutes two research projects aiming at driving therapeutic advances.
CONDITIONS
Official Title
Advanced Translational Research on Childhood Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of acute lymphoblastic leukemia (ALL) or
- Diagnosis of acute myeloid leukemia (AML) or
- Diagnosis of mixed phenotype acute leukemia (MPAL) or
- Diagnosis of juvenile myelomonocytic leukemia (JMML) or
- Diagnosis of myelodysplastic syndromes (MDS) or
- Being a normal bone marrow donor
You will not qualify if you...
- Unable to understand English or Chinese
- Patient or parent refuses to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hong Kong Children Hospital
Hong Kong, Hksar, China
Actively Recruiting
Research Team
K
Kathy Chan, Ph. D.
CONTACT
K
Kam Tong Leung, Ph. D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here